IDEAYA Biosciences’ (IDYA) Overweight Rating Reiterated at Stephens

Stephens restated their overweight rating on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a report published on Friday,Benzinga reports. They currently have a $50.00 price target on the stock.

A number of other brokerages also recently weighed in on IDYA. Oppenheimer reissued an “outperform” rating and set a $53.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Leerink Partners downgraded shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $41.00 to $27.00 in a research note on Tuesday, November 5th. UBS Group assumed coverage on shares of IDEAYA Biosciences in a research note on Thursday, October 24th. They issued a “buy” rating and a $50.00 price target for the company. Leerink Partnrs downgraded shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $53.58.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ:IDYA opened at $21.00 on Friday. The firm has a market cap of $1.82 billion, a PE ratio of -9.01 and a beta of 0.82. The firm’s fifty day moving average is $24.36 and its 200-day moving average is $29.88. IDEAYA Biosciences has a 52 week low of $20.63 and a 52 week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.00 million. Sell-side analysts forecast that IDEAYA Biosciences will post -2.45 EPS for the current year.

Institutional Trading of IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of IDYA. Creative Planning bought a new stake in IDEAYA Biosciences during the 3rd quarter worth approximately $275,000. Values First Advisors Inc. bought a new position in shares of IDEAYA Biosciences in the 3rd quarter worth $74,000. Allworth Financial LP increased its holdings in shares of IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock worth $29,000 after buying an additional 800 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of IDEAYA Biosciences by 35.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company’s stock worth $94,000 after buying an additional 796 shares during the last quarter. Finally, abrdn plc bought a new position in shares of IDEAYA Biosciences in the 3rd quarter worth $7,376,000. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.